- Home
- MHF vs CRGX Comparison
MHF vs CRGX Comparison
Compare MHF & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHF
- CRGX
- Stock Information
- Founded
- MHF 1988
- CRGX 2021
- Country
- MHF United States
- CRGX United States
- Employees
- MHF N/A
- CRGX N/A
- Industry
- MHF Finance/Investors Services
- CRGX
- Sector
- MHF Finance
- CRGX
- Exchange
- MHF Nasdaq
- CRGX Nasdaq
- Market Cap
- MHF N/A
- CRGX 213.7M
- IPO Year
- MHF N/A
- CRGX 2023
- Fundamental
- Price
- MHF $7.05
- CRGX $4.51
- Analyst Decision
- MHF
- CRGX Hold
- Analyst Count
- MHF 0
- CRGX 7
- Target Price
- MHF N/A
- CRGX $4.67
- AVG Volume (30 Days)
- MHF 57.2K
- CRGX 858.6K
- Earning Date
- MHF 01-01-0001
- CRGX 05-13-2025
- Dividend Yield
- MHF 4.29%
- CRGX N/A
- EPS Growth
- MHF N/A
- CRGX N/A
- EPS
- MHF N/A
- CRGX N/A
- Revenue
- MHF N/A
- CRGX N/A
- Revenue This Year
- MHF N/A
- CRGX $58.18
- Revenue Next Year
- MHF N/A
- CRGX N/A
- P/E Ratio
- MHF N/A
- CRGX N/A
- Revenue Growth
- MHF N/A
- CRGX N/A
- 52 Week Low
- MHF $5.92
- CRGX $3.00
- 52 Week High
- MHF $6.79
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- MHF 41.35
- CRGX 53.99
- Support Level
- MHF $6.87
- CRGX $4.42
- Resistance Level
- MHF $7.09
- CRGX $4.77
- Average True Range (ATR)
- MHF 0.18
- CRGX 0.26
- MACD
- MHF -0.01
- CRGX 0.06
- Stochastic Oscillator
- MHF 32.73
- CRGX 78.15
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.